OS Therapies said the UK Medicines and Healthcare products Regulatory Agency (MHRA) will lead the global regulatory review of its OST-HER2 cancer immunotherapy under Project Orbis. The company also completed a U.S. Food and Drug Administration (FDA) Type C meeting focused on statistical methods for OST-HER2. MHRA alignment supports an upcoming regulatory submission, although the announcement excerpt does not identify its specific type.